Treatment of Coexisting Lichen Planus and Psoriasis
For patients with both lichen planus and psoriasis, JAK inhibitors—specifically upadacitinib—represent the most effective single-agent therapy that can address both conditions simultaneously, based on recent case evidence showing marked improvement in both diseases.
Treatment Algorithm
First-Line Approach: Topical Therapy
- Topical corticosteroids (e.g., mometasone furoate) for 4-8 weeks can be initiated for both conditions when disease is mild 1
- Add emollients to reduce itching, desquamation, and prevent quick relapse when corticosteroids are discontinued 1
- For lichen planus specifically, topical calcineurin inhibitors are also first-line options
Second-Line: Oral Retinoids
- Acitretin has demonstrated efficacy for both psoriasis and lichen planus overlap cases 2, 3
- Can be combined with narrowband UVB (NBUVB) phototherapy for enhanced effect 3
- However, patient adherence may be limited by safety concerns and side effects 2
Third-Line: JAK Inhibitors (Preferred for Moderate-to-Severe or Refractory Disease)
Upadacitinib emerges as the optimal systemic choice for several reasons:
- Dual efficacy: Recent case reports demonstrate complete resolution of both erosive oral lichen planus and psoriasis with upadacitinib 30 mg daily 2, 4
- Mechanism: JAK1 inhibition addresses the shared inflammatory pathways—both conditions show JAK1 and JAK3 overexpression in inflammatory infiltrates 4
- Dosing: Start at 15 mg daily, escalate to 30 mg if needed for complete disease control 4
- Timeline: Expect marked improvement within 3 months 2
Alternative Systemic Options
For psoriasis-predominant disease:
- Biologics: IL-12/23 inhibitors (ustekinumab) or IL-23 inhibitors (risankizumab, tildrakizumab) are effective for psoriasis 5, 6
- Avoid IL-17 inhibitors if any concern for inflammatory bowel disease exists 5
- Newer agents like deucravacitinib and bimekizumab show promise for nail involvement 6
For lichen planus-predominant disease:
- Systemic corticosteroids (short-term)
- Methotrexate (effective for both conditions) 7
- Mycophenolate (though may be ineffective in refractory cases) 4
Critical Clinical Considerations
Common Pitfalls to Avoid
- Sequential monotherapy failure: Switching between agents targeting only one condition (e.g., apremilast for psoriasis, then separate lichen planus treatment) leads to prolonged disease burden 4
- Premature discontinuation: Patients may stop effective treatments like acitretin due to safety concerns—counseling is essential 2
- Inadequate dosing: Upadacitinib may require dose escalation to 30 mg for complete control of both conditions 4
Disease Interplay
- Both conditions share altered T-cell-mediated autoimmunity and cytokine dysregulation 3, 8
- Koebner phenomenon may be present in both, complicating clinical presentation 3
- The coexistence is rare (psoriasis affects 2-3%, lichen planus 1% of population, overlap is exceptional) 3
Monitoring Requirements
- For JAK inhibitors: Screen for infections, monitor CBC, lipids, and liver function
- For biologics: TB screening, hepatitis panel, infection surveillance
- For acitretin: Lipids, liver function, pregnancy prevention (teratogenic)
Nuances in Evidence Quality
The evidence base differs significantly between conditions:
- Psoriasis treatment: Robust guideline support from AAD-NPF with multiple high-quality RCTs 5, 1
- Lichen planus treatment: Severely limited literature, mainly case reports and small series 7
- Overlap syndrome: Only recent case reports available, but these show compelling results with JAK inhibition 2, 4
The strength of recent case evidence (2024-2026) for upadacitinib in this specific overlap scenario, combined with its mechanistic rationale targeting shared inflammatory pathways, makes it the most rational choice for patients requiring systemic therapy.